Literature DB >> 12522834

Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.

F Perez-Ruiz1, M Calabozo, G García Erauskin, A Ruibal, A M Herrero-Beites.   

Abstract

OBJECTIVE: To compare renal handling of uric acid in patients with primary gout with that of a control group.
METHODS: A case-control study of 100 patients with primary gout and 72 healthy controls was undertaken. Creatinine clearance, uric acid clearance, 24-hour uric acid urinary excretion, fractional excretion of uric acid, excretion of uric acid per volume of glomerular filtration, urinary uric acid to creatinine ratio, and glomerular uric acid filtered load were calculated using 24-hour urine samples. After treatment with allopurinol to achieve similar glomerular filtered load of uric acid, patients were again compared with controls.
RESULTS: Patients with gout showed lower uric acid clearance, fractional excretion of uric acid, excretion of uric acid per volume of glomerular filtration, and urinary uric acid to creatinine ratio than controls at baseline, when patients showed hyperuricemia. Although the glomerular uric acid filtered load was much higher in patients with gout than controls, 24-hour uric acid excretion was not statistically different. After treatment with allopurinol, and achieving similar uric acid filtered loads, patients still showed lower figures than controls. When patients with 24-hour urinary uric acids levels >700 mg/day were compared with controls, they had lower uric acid clearance and fractional excretion of uric acid than controls, both at baseline and after achieving similar filtered loads with allopurinol therapy.
CONCLUSIONS: Renal underexcretion is the main mechanism for the development of primary hyperuricemia in gout, but even patients showing apparent high 24-hour uric acid output show lower uric acid clearance than controls, indicating that relative, low-grade underexcretion of uric acid is at work.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12522834     DOI: 10.1002/art.10792

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  60 in total

1.  Perfluoroalkyl acids, hyperuricemia and gout in adults: Analyses of NHANES 2009-2014.

Authors:  Franco Scinicariello; Melanie C Buser; Lina Balluz; Kimberly Gehle; H Edward Murray; Henry G Abadin; Roberta Attanasio
Journal:  Chemosphere       Date:  2020-06-20       Impact factor: 7.086

Review 2.  Diagnosis and management of gout: a rational approach.

Authors:  E Suresh
Journal:  Postgrad Med J       Date:  2005-09       Impact factor: 2.401

3.  Gout, diuretics and the kidney.

Authors:  E Pascual; M Perdiguero
Journal:  Ann Rheum Dis       Date:  2006-08       Impact factor: 19.103

Review 4.  The challenges of gout management in the elderly.

Authors:  Lisa K Stamp; Sarah Jordan
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

5.  Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Authors:  Claudio Borghi; Justyna Domienik-Karłowicz; Andrzej Tykarski; Krystyna Widecka; Krzysztof J Filipiak; Miłosz J Jaguszewski; Krzysztof Narkiewicz; Giuseppe Mancia
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 2.737

Review 6.  Management of acute and chronic gouty arthritis: present state-of-the-art.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Genome-Wide Association Studies of Metabolites in Patients with CKD Identify Multiple Loci and Illuminate Tubular Transport Mechanisms.

Authors:  Yong Li; Peggy Sekula; Matthias Wuttke; Judith Wahrheit; Birgit Hausknecht; Ulla T Schultheiss; Wolfram Gronwald; Pascal Schlosser; Sara Tucci; Arif B Ekici; Ute Spiekerkoetter; Florian Kronenberg; Kai-Uwe Eckardt; Peter J Oefner; Anna Köttgen
Journal:  J Am Soc Nephrol       Date:  2018-03-15       Impact factor: 10.121

8.  Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Authors:  R A Wermers; C P Recknor; F Cosman; L Xie; E V Glass; J H Krege
Journal:  Osteoporos Int       Date:  2008-02-19       Impact factor: 4.507

Review 9.  Gout: optimizing treatment to achieve a disease cure.

Authors:  José Antonio Bernal; Neus Quilis; Mariano Andrés; Francisca Sivera; Eliseo Pascual
Journal:  Ther Adv Chronic Dis       Date:  2016-01-12       Impact factor: 5.091

10.  Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout.

Authors:  F Cardona; F J Tinahones; E Collantes; A Escudero; E García-Fuentes; F J Soriguer
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.